Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, Dec. 15, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that on December 7, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 10,500 shares of its common stock to one new employee, consisting of inducement stock options to purchase an aggregate of 7,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 3,500 shares of its common stock.
Related news for (RYTM)
- Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program
- Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
- Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
- Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
- Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity